Daniel Einhorn
Cardiovascular Disease · Chandler, AZNPI 1215996186
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,450 of the $12,848 with a category attached, or 73.6%. Abbott accounts for 77.0% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2020 at $7,194 and has fallen 83.5% since, to $1,184 in 2022.
Across 188 payments — averaging $68.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$10K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$271
- Johnson & Johnson$269
- Bardy Diagnostics, Inc.$245
- AstraZeneca$224
- Novartis$204
- plus $2K from 24 others
Across 3 payments — averaging $653.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2K
- Novartis$460
What the payments were for
- Speaking & faculty fees$9,45074%
- Food & beverage$3,26225%
- Education$1361%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 24 | $9,888 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $271 |
| Johnson & Johnson | 20 | $269 |
| Bardy Diagnostics, Inc. | 9 | $245 |
| AstraZeneca | 10 | $224 |
| Novartis | 14 | $204 |
| Boston Scientific | 5 | $204 |
| Novo Nordisk | 12 | $190 |
| Merck | 10 | $147 |
| Boehringer Ingelheim | 7 | $143 |
| Amgen | 8 | $119 |
| Pfizer | 8 | $116 |
| Regeneron Healthcare Solutions, Inc. | 6 | $103 |
| Esperion Therapeutics, Inc. | 3 | $87 |
| Amarin Pharma, Inc. | 6 | $84 |
| Sanofi-aventis U.S. LLC | 4 | $73 |
| Edwards Lifesciences | 3 | $68 |
| Astellas Pharma US Inc | 4 | $61 |
| Kowa Pharmaceuticals America, Inc. | 3 | $46 |
| Tactile Systems Technology Inc | 3 | $38 |
| Arbor Pharmaceuticals, Inc. | 2 | $38 |
| Impulse Dynamics (USA) Inc. | 2 | $32 |
| Alnylam Pharmaceuticals Inc. | 2 | $31 |
| Philips North America LLC | 1 | $30 |
| Medtronic | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Biocompatibles, Inc. | 1 | $25 |
| Atricure, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,848 in reported general payments places this provider in the 80th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Chandler
- Marc SilverChandler$173K
- Gautam KediaChandler$18K
- Akarsh ParekhChandler$15K
- Ashish GuptaPhoenix$1.1M
- Rajkumar SugumaranPhoenix$957K
- Krishnaswami VijayaraghavanScottsdale$927K
- Steven MottlTucson$340K
- Paul UnderwoodScottsdale$259K
- Omar WaniFlagstaff$244K
- Robert BurkeScottsdale$207K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.